Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis

American Journal of Health-System Pharmacy

Volumn 64, Issue 24, 2007, Pages 2561-2568

  Greene, Reginald E ^a,b   Mauskopf, Josephine ^c   Roberts, Craig S ^d   Zyczynski, Teresa ^e   Schlamm, Haran T ^f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c RTI INTERNATIONAL   (United States)

^d PFIZER INC   (United States)

^e General Electric Health Care   (United States)

^f Pf Izer Global Research and Development   (United States)

Author keywords

Amphotericin B; Antifungals; Aspergillosis; Drug comparisons; Economics; Methodology; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH SERVICE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 37249076405     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060584     Document Type: Article

References (22)

1. Marchant N. Drivers of growth in medical expenditure. London: Office of Health Economics; 1997.
2. Fraser VJ, Jones M, Dunkel J et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis. 1992; 15:414-21.
3. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis. 1998; 27:781-8.
4. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis. 2000; 31:1524-8. [Erratum, Clin Infect Dis. 2001; 32:673.]
5. Wilson LS, Reyes CM, Stolpman M et al. The direct cost and incidence of systemic fungal infections. Value Health. 2002; 5:26-34.
6. Caillot D, Casasnovas O, Bernard A et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997; 15:139-47.
7. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007; 44:373-9.
8. Caillot D, Mannone L, Cuisenier B et al. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin Microbiol Infect. 2001; 7(suppl 2):54-61.
9. Orr DP, Myerowitz RL, Dubois PJ. Pathoradiologic correlation of invasive pulmonary aspergillosis in the compromised host. Cancer. 1978; 41:2028-39.
10. Caillot D, Couaillier JF, Bernard A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 2001; 19:253-9.
11. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347:408-15.
12. Drug topics redbook 2004. Montvale, NJ: Medical Economics; 2004.
13. Healthcare Cost and Utilization Project. Design of the HCUP nationwide inpatient sample, 2002. www.hcup-us.ahrq.gov/db/nation/nis/reports/ NIS_2002_Design_Report.pdf (accessed 2006 Apr 1).
14. Centers for Medicare and Medicaid Services. National physician fee schedule payment amount file, 2005. www.cms.hhs.gov/PhysicianFeeSched (accessed 2006 Apr 1).
15. Wenzel R, Del Favero A, Kibbler C et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother. 2005; 55:352-61.
16. Centers for Medicare and Medicaid Services. MEDPAR files. www.cms.hhs.gov/MedicareFeeforSvcPartsAB/03_MEDPAR.asp (accessed 2007 Jun 6).
17. Drummond MF, O'Brien BJ, Stoddart GL et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford Univ. Press; 1997.
18. Gold MR, Siegel JE, Russell LB et al., eds. Cost-effectiveness in health and medicine. New York: Oxford Univ. Press; 1996.
19. Rotstein C, Laverdière M, Marciniak A et al. An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada. Can J Infect Dis Med Microbiol. 2004; 15:277-84.
20. Jansen JP, Meis JF, Blijlevens NM et al. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Curr Med Res Opin. 2005; 21:1535-46.
21. Jansen JP, Kern WV, Comely OA et al. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health. 2006; 9:12-23. [Erratum, Value Health. 2006; 9:359.]
22. Lewis JS, Boucher HW, Lubowski TJ et al. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis. Pharmacotherapy. 2005; 25:839-46.